RxDoctor Payments Data

Sophia Koo, MD

Infectious Disease · Boston, MANPI 1174581771

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,125 of the $31,192 with a category attached, or 67.7%. Reporting peaked in 2019 at $16,867 and has fallen 83.0% since, to $2,875 in 2025. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,192in general payments, 2019–2025

Across 16 payments — averaging $1949.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$18K
  • Vertex$13K
$4,873,932in research payments, 2019–2025

Across 59 payments — averaging $82,609 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$4.1M
  • Astrazeneca UK Limited$521K
  • Merck$208K
  • Pfizer$46K

What the payments were for

  • Consulting fees$21,12568%
  • Travel & lodging$9,98332%
  • Food & beverage$840%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck11$18,142
Vertex5$13,050

How this compares

$31,192 in reported general payments places this provider in the 90th percentile of 368 infectious disease providers in Massachusetts.

See all infectious disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$53,838
Medicare patients
144
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →